Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics
Rhea-AI Summary
Akari Therapeutics (Nasdaq: AKTX) announced a strategic research collaboration with Whitehawk Therapeutics to evaluate combining Akari’s proprietary PH1 spliceosome-modulating payload with Whitehawk’s topoisomerase I inhibitor (TOP1i) ADC platform. The collaboration focuses on preclinical research in oncology antibody drug conjugates (ADCs).
Under the agreement, Akari will lead the design, execution and evaluation of a series of focused preclinical studies. Initial work will span multiple preclinical workstreams assessing dual-payload compatibility and potential synergies, generating data intended to inform future development decisions and potential broader collaboration between the companies. According to Akari, the program aims to further validate PH1’s differentiated mechanism and explore development of a potential first-in-class dual-payload ADC technology. Whitehawk views dual-payload approaches as a possible next opportunity to expand its ADC platform. The collaboration is expected to start immediately, with interim data updates anticipated as studies progress, and both companies will jointly review results to determine whether they support expanded development discussions.
Positive
- None.
Negative
- None.
News Market Reaction – AKTX
In the Jul 21 session, AKTX declined 12.80%, reflecting a significant negative market reaction. Argus tracked a peak move of +5.3% during that session. Argus tracked a trough of -26.4% from its starting point during tracking. Our momentum scanner triggered 14 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Previous Partnership Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 09 | Partnership discussion | Positive | +1.0% | Management discussed the WuXi XDC partnership and expected IND acceleration. |
| Apr 06 | Strategic partnership | Positive | -20.8% | WuXi XDC partnership advanced Akari’s PH1 ADC payload development. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Partnership-tagged announcements produced mixed reactions, with one positive and one negative outcome and an average move of -9.89%.
Key Terms
adc medical
rna splicing modulator medical
topoisomerase i inhibitor medical
preclinical studies medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Collaboration will evaluate Akari's PH1 payload technology in combination with Whitehawk's TOP1i payload to generate potential future development opportunities
TAMPA, Fla. and LONDON, July 21, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced a strategic research collaboration with Whitehawk Therapeutics, a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently develop improved ADC cancer treatments. Under the collaboration, the companies will conduct a series of focused preclinical studies evaluating Akari's proprietary PH1 spliceosome-modulating payload technology in combination with Whitehawk’s topoisomerase I inhibitor (TOP1i) ADC platform.
Akari will lead the design, execution and evaluation of the research activities. The initial collaboration will include multiple preclinical workstreams designed to assess dual payload compatibility and synergies, while generating data intended to guide future development decisions and potential broader collaboration opportunities between the companies.
“This collaboration marks an important first step in exploring the broader potential of our PH1 payload technology to combine in unique ways with current classes of ADC payloads across the field to advance ADC innovation and impact,” said Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics. “Whitehawk brings a differentiated ADC platform and strong expertise in evaluating novel ADC technologies. We believe the planned studies will provide further validation of PH1's differentiated mechanism and support development of a dual payload technology that will be first-in-class for novel ADCs to attack cancer.”
“Beyond our existing portfolio, we see dual-payload approaches as a potential next opportunity to expand the therapeutic potential of our ADC platform,” said Dave Lennon, PhD, President and Chief Executive Officer of Whitehawk Therapeutics. “We are pleased to enter this collaboration with Akari to understand whether combining these differentiated mechanisms has the potential to support future development.”
The collaboration is expected to commence immediately, with interim data updates anticipated as studies progress. Both companies will jointly review resulting data and determine whether findings support broader development discussions.
About Akari Therapeutics
Akari Therapeutics is an oncology biotechnology company developing next-generation antibody drug conjugates (ADCs) with a unique payload, PH1, which targets RNA splicing. Utilizing its innovative ADC discovery platform, the Company has the ability to generate ADC candidates and optimize them based on the desired application to any antigen target of interest. Akari’s lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells with a proprietary linker, enabling it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. Unlike current ADCs that use microtubule inhibitors and DNA-damaging agents as their payloads, PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. This splicing modulation has been shown in preclinical animal models to induce cancer cell death while activating both the innate and adaptive immune systems to drive robust and durable activity. In preclinical studies, AKTX-101 has been shown to have significant activity and prolonged survival relative to ADCs with traditional payloads. Additionally, AKTX-101 has the potential to be synergistic with checkpoint inhibitors and has demonstrated prolonged survival as both a single agent and in combination with checkpoint inhibitors. The PH1 payload has also been demonstrated to be very active against cancer cells with key oncogenic drivers such as KRAS, BRAF, ARV7, FGFR3 fusions, and others. The Company has initiated IND-enabling studies for AKTX-101 with a goal of starting its first-in-human trial by mid-2027. Akari is also developing AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen broadly expressed across multiple solid tumors. AKTX-102 is designed to leverage Akari’s proprietary PH1 spliceosome-modulating payload and a novel antibody construct to enable differentiated tumor cell killing and immune activation.
For more information about the Company, please visit www.akaritx.com and connect on X and LinkedIn.
About Whitehawk Therapeutics
Whitehawk Therapeutics is a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently develop improved cancer treatments. Whitehawk's portfolio includes HWK-007, HWK-016 and HWK-206, ADCs engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. These assets are in-licensed from WuXi Biologics under an exclusive development and global commercialization agreement.
Whitehawk's underlying ADC platform leverages CPT113 as the core linker-payload technology, enhanced with its proprietary Carbon Bridge Cysteine Re-pairing (CBCR) bioconjugation process to support improved stability and therapeutic index. Whitehawk has an option agreement with Hangzhou DAC for access to CPT113 for use in up to five additional ADC programs.
More information on the Company is available at www.whitehawktx.com and connect with us on LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
This press release includes express or implied forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, about the Company that involve risks and uncertainties relating to future events and the future performance of the Company. Actual events or results may differ materially from these forward-looking statements. Words such as “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “future,” “opportunity” “will likely result,” “target,” variations of such words, and similar expressions or negatives of these words are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of such forward-looking statements include, but are not limited to, express or implied statements regarding the ability of the Company to advance its product candidates for the treatment of cancer and the timing of commencement of a Phase I clinical trial. These statements are based on the Company’s current plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific. A number of important factors, including those described in this communication, could cause actual results to differ materially from those contemplated in any forward-looking statements. Factors that may affect future results and may cause these forward-looking statements to be inaccurate include, without limitation: the Company’s need for additional capital; the potential impact of unforeseen liabilities, future capital expenditures, revenues, costs, expenses, earnings, synergies, economic performance, indebtedness, financial condition and losses on the future prospects, business and management strategies for the management, expansion and growth of the business; risks related to global as well as local political and economic conditions, including interest rate and currency exchange rate fluctuations; potential delays or failures related to research and/or development of the Company’s programs or product candidates; risks related to any loss of the Company’s patents or other intellectual property rights; any interruptions of the supply chain for raw materials or manufacturing for the Company’s product candidates, including as a result of potential tariffs; the nature, timing, cost and possible success and therapeutic applications of product candidates being developed by the Company and/or its collaborators or licensees; the extent to which the results from the research and development programs conducted by the Company, and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; uncertainty of the utilization, market acceptance, and commercial success of the Company’s product candidates; risks related to competition for the Company’s product candidates; and the Company’s ability to successfully develop or commercialize its product candidates. While the foregoing list of factors presented here is considered representative, no list should be considered to be a complete statement of all potential risks and uncertainties. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the SEC, copies of which may be obtained from the SEC’s website at www.sec.gov. The Company assumes no, and hereby disclaims any, obligation to update the forward-looking statements contained in this press release except as required by law.
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
AKTX@jtcir.com
